State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Ryan, CE.; Ahn, IE.; Sekar, A.; Rawstron, A.; Almeida, J.; Martin-Subero, I.; Parry, EM.; Alcoceba, M.; Calado, DP.; Orfao, A.; Langerak, AW.; Veelken, H.; Langerbeins, P.; Stephens, DM.; Parikh, SA.; Niemann, CU.; Roulland, S.; Stamatopoulos, K.; Slager, SL.; Shanafelt, T.; Ghia, P.; Okosun, J.; Davids, MS.

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

All Authors

Ryan, CE.

Ahn, IE.

Sekar, A.

Rawstron, A.

Almeida, J.

Martin-Subero, I.

Parry, EM.

Alcoceba, M.

Calado, DP.

Orfao, A.

Show 10 more

LTHT Author

Rawstron, Andy

LTHT Department

Oncology
Leeds Cancer Centre
Haematological Malignancy Diagnostic Service

Non Medic

Clinical Scientist

Publication Date

2025

Item Type

Journal Article

Abstract

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.